ASBPW — Aspire Biopharma Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1847345 ·
Last close
$0.02
Market Cap
—
52W High
$0.02
52W Low
$0.02
ADV30
901
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 28,353 | 5,750 | -1,646,169 | -3,222,892 | 7,117,147 | 5,857,024 | 3,248,684 |
| Dec 2025 | 4,261 | -1,000 | -1,849,424 | -4,707,734 | 1,312,166 | 1,003,904 | 7,688,495 |
| Sep 2025 | 1,941 | 884 | -1,145,497 | -1,850,493 | 2,403,129 | 1,948,271 | 13,870,407 |
| Jun 2025 | 0 | — | -799,890 | -1,981,293 | 989,422 | 206,233 | 10,606,207 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,210,482
Investing CF
$38,258
Financing CF
$10,720,963
CapEx
$-18,822
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-30,480,973
Inventory
$369,974
Receivables
$0
ST Investments
—
EBIT TTM
$-1,925,753
Pretax Income TTM
$-11,762,412
Interest Exp TTM
$9,836,659
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$34,555
EBITDA
—
Free Cash Flow
$-1,016,107
Enterprise Value
—
Total Cash
$5,857,024
Total Debt
$1,499,214
Shares Out
—
Trailing EPS
—
Book Value
$23.10
ROE
—
ROA
-74.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,202 | -19,351,291 | -24,480,848 | 1,312,166 | 7,688,495 | — | -4,923,488 |
| Dec 2024 | 0 | -1,210,871 | -1,309,872 | 147,989 | 1,688,077 | — | -265,186 |
| Dec 2023 | 0 | -1,340,168 | 4,464,079 | 46,174 | 534,035 | — | 11,136 |
| Dec 2022 | 0 | -596,491 | -597,117 | 22,538 | 151,328 | — | -142,905 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1188.58 | — |
| JNJ | JOHNSON & JOHNSON | $618.61B | $256.98 | — |
| ABBV | AbbVie Inc. | $438.31B | $248.08 | — |
| NVSEF | NOVARTIS AG | $305.29B | $160.00 | — |
| MRK | Merck & Co., Inc. | $305.12B | $123.54 | — |
News headlines (Yahoo Finance, 1h cache)
OTC Markets Life Sciences Investor Forum: Stephen Quesenberry, General Counsel and Director of Product Development, of Aspire Biopharma with Zacks SCR’s David Bautz, PhD
2026-07-10 10:33 · Yahoo
Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs
2026-06-24 12:30 · Yahoo
Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th
2026-06-17 14:57 · Yahoo
Aspire Biopharma Acquires Automotive Supplier Dura Driver Control Systems in $30M Deal (ASBP)
2026-06-12 14:20 · Yahoo
ASBP Stock Heads For Best Week In Over 2 Months – Why This Drug Delivery Tech Firm Is Buying An Auto Supplier?
2026-06-12 14:14 · Yahoo
Aspire Biopharma Issues Shareholder Letter
2026-05-28 12:30 · Yahoo
Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members
2026-05-27 12:30 · Yahoo
Aspire Biopharma (ASBP) Authorizes $5M Share Repurchase Program
2026-05-13 17:46 · Yahoo
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio
2026-05-07 15:00 · Yahoo
Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition
2026-04-20 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.